Business Context and Reporting Period
MEDICINOVA INC filed a Form 8-K on July 27, 2017, to disclose a Japanese financial report ("Kessan Tanshin") submitted to the Tokyo Stock Exchange. This filing supplements the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, by providing a financial forecast for the six months and full year ending December 31, 2017.
Key Financial Metrics and Guidance
The filing provides a full-year forecast for 2017 rather than historical results for the quarter ended June 30, 2017. The specific forecasted metrics are:
- Revenues: $0 (Forecast for full year 2017)
- Operating Loss: $12,654,000 (Forecast for full year 2017)
- Net Loss: $12,654,000 (Forecast for full year 2017)
- Loss Per Share: Expected basic and diluted loss of $0.35 for the full year 2017.
The loss per share calculation assumes a weighted average of 35,800,000 shares. The filing does not provide specific historical revenue, cash flow, debt, or liquidity figures for the quarter ended June 30, 2017, referring instead to the Form 10-Q for those details.
Material Changes and Supplementary Information
The primary material addition in this filing is the inclusion of financial statements denominated in Japanese yen as supplementary information. These figures were translated using an exchange rate of 112.00 Japanese yen per U.S. dollar, based on the Telegraphic Transfer Middle Rate as of June 30, 2017. No specific material changes to operations or financial position compared to the prior period are detailed in this text, other than the provision of the forward-looking forecast.
Risks, Contingencies, and Management Commentary
Management emphasizes that the forecast is based on assumptions regarding current conditions, trends, and future developments. The filing includes extensive disclaimers regarding forward-looking statements, noting that actual results may differ materially due to risks beyond the Company's control. Key risks identified include:
- Regulatory approval timelines and outcomes for product candidates.
- Progress and results of pending clinical trials, including enrollment delays.
- Potential adverse side effects or inadequate therapeutic efficacy.
- Challenges in development, testing, manufacturing, and marketing.
- Intellectual property protection and patent validity.
- Market competition and the ability to secure strategic partnerships.
- Liquidity risks and the ability to raise sufficient capital or debt financing.
The Company's independent auditors have not compiled or reviewed the forecasted financial results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the historical financial results for the quarter ended June 30, 2017, in the separate Form 10-Q filing.
- Confirm the current cash position and liquidity runway, as the forecast indicates zero revenue and significant operating losses.
- Review the status of ongoing clinical trials and regulatory submissions to assess the validity of the zero-revenue forecast.
- Monitor the Company's ability to raise capital given the projected net loss of $12.65 million for the year.
- Check for any updates to the weighted average share count, as the EPS forecast relies on a specific figure of 35,800,000 shares.